RO7047650, Tecentriq 1 200 mg concentrate for solution for infusion clinical trials

A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination with Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment

This study looks at a new combination treatment for advanced kidney cancer that has grown despite earlier immune-boosting treatment. Researchers want to see if combining two drugs, Atezolizumab and Cabozantinib, works better than Cabozantinib alone to control the cancer and help people live longer.